Cytotoxicity News and Research

RSS

Neutralizing monoclonal antibodies provide Fc receptor-independent SARS-CoV-2 protection in Hamsters

A study published in the journal mBio analyzes the capacity of the neutralizing MAb 2B04 to protect different antibody titers.

16 Sep 2021

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

A new paper describes the results of a randomized controlled trial of CP in adult COVID-19 patients on oxygen when used within 12 days of the onset of respiratory symptoms.

14 Sep 2021

Artemisia plant extract prevents SARS-CoV-2 replication in vitro

A new study describes the beneficial effect of an extract of Artemisia annua when used to treat cells in culture exposed to SARS-CoV-2.

13 Sep 2021

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

This study revealed that the CV3-13 antibody can mediate Fc effector functions against S protein-expressing cells.

13 Sep 2021

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.

3 Sep 2021

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

In a paper recently uploaded to the bioRxiv* preprint server, structure-based ASOs are developed against SARS-CoV-2, intended to bond with RNA in its structured in situ form, rather than the more rarely encountered linear section, achieving greater affinity and specificity than linear ASOs, and demonstrating inhibition of virus replication in human cells.

30 Aug 2021

Compounds from medicinal mushrooms may be our future weapon against SARS-CoV-2

Certain steroid-like compounds from Taiwan's endemic medicinal mushrooms (known as antcins) may inhibit a host cell receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, thus, prevent viral infection and subsequent development of the coronavirus disease (COVID-19), reports a new study published in the MDPI's journal Plants.

24 Aug 2021

Peptoids could one day cure or prevent herpes, COVID-19

In addition to antibodies and white blood cells, the immune system deploys peptides to fight viruses and other pathogens.

24 Aug 2021

Antiviral strategy using synthetic peptoid has promising implications for fighting infection

Scientists have manufactured a synthetic form of peptide to combat viral infections, with tests already conducted on HSV-1 as well as SARS-CoV-2.

24 Aug 2021

Study defines SARS-CoV-2 antibodies associated with neutralization and effector functions

A new study explores the polyclonal antibody response to SARS-CoV-2 in greater detail.

10 Aug 2021

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

COVID vaccines generate antibodies in saliva

Researchers in the United States and Canada have conducted a study showing that the vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) generate local antibody responses in the salivary gland that are independent of the systemic immune response.

5 Aug 2021

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

BNT162b2 vaccine shows high efficacy at six months

The Pfizer/BioNTech vaccine appears to be highly effective in protecting against the SARS-CoV-2 infection, including its relatively resistant beta variant B.1.351.

30 Jul 2021

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

Budesonide’s antiviral effect against SARS-CoV-2

A new study examines the in vitro antiviral effect of pure budesonide and Pulmicort® against the SARS-CoV-2 WT and two VoCs.

26 Jul 2021

Rosin soap as a potential SARS-CoV-2 disinfectant

In a research paper recently uploaded to the preprint server bioRxiv* by Bell et al. (July 19th, 2021), the potential of rosin soap as a virucide is investigated, finding a ten-thousand-fold drop in infectivity against enveloped viruses such as influenza and SARS-CoV-2 in particular.

26 Jul 2021

COVID-19 researchers review 184 drug repurposing candidates

New research describes the use of integrative bioinformatics analyses of transcriptomic profiles for COVID-19 therapeutics.

15 Jul 2021

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. The nanodiamonds proved to be a powerful and versatile platform for antigen conjugation. This could make it a safe and effective strategy for the production of off-the-shelf vaccines against multiple coronaviruses.

13 Jul 2021

Natural compound 'pheophorbide a' demonstrates robust antiviral activity against SARS-CoV-2 in vitro

A team of scientists from France has recently demonstrated photosensitive antiviral activity of the natural compound pheophorbide a (Pba) against a broad range of enveloped viruses, including coronaviruses.

12 Jul 2021

Cytotoxicity News and Research

Neutralizing monoclonal antibodies provide Fc receptor-independent SARS-CoV-2 protection in Hamsters

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

Artemisia plant extract prevents SARS-CoV-2 replication in vitro

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

Antisense oligonucleotides engineered to inhibit SARS-CoV-2

Compounds from medicinal mushrooms may be our future weapon against SARS-CoV-2

Peptoids could one day cure or prevent herpes, COVID-19

Antiviral strategy using synthetic peptoid has promising implications for fighting infection

Study defines SARS-CoV-2 antibodies associated with neutralization and effector functions

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

COVID vaccines generate antibodies in saliva

Pfizer moves towards an oral anti-COVID-19 therapy

BNT162b2 vaccine shows high efficacy at six months

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

Budesonide’s antiviral effect against SARS-CoV-2

Rosin soap as a potential SARS-CoV-2 disinfectant

COVID-19 researchers review 184 drug repurposing candidates

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

Natural compound 'pheophorbide a' demonstrates robust antiviral activity against SARS-CoV-2 in vitro

Forensics And Toxicology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News